Market Size of Middle East And Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry
| Study Period | 2019- 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 758.32 Million |
| Market Size (2029) | USD 893.21 Million |
| CAGR (2024 - 2029) | 3.60 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Middle East and Africa Dipeptide Peptidase 4 (DPP-4) inhibitors Market Analysis
The Middle East And Africa Dipeptide Peptidase 4 Inhibitors Market size is estimated at USD 758.32 million in 2024, and is expected to reach USD 893.21 million by 2029, growing at a CAGR of 3.60% during the forecast period (2024-2029).
The COVID-19 pandemic positively impacted the Middle East and Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Market. Diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes in patients with COVID-19 including an increased risk of severe illness or death. People with diabetes have a weaker immune system, the COVID-19 complication aggravates the condition, and the immune system gets weaker very fast. People with diabetes have more chances to get into serious complications rather than normal people.
Dipeptidyl peptidase 4 (DPP-4) inhibitors are a class of medicine that lower high blood glucose levels and are used in the treatment of type 2 diabetes. DPP4 inhibitors increase insulin and GLP-1 secretion and are commonly prescribed for people suffering from type 2 diabetes. The use of DPP4 inhibitors in patients with COVID-19 with or even without type 2 diabetes offers a simple way to reduce the virus entry and replication into the airways and to hamper the sustained cytokine storm and inflammation within the lung in patients diagnosed with COVID-19 infection.
The diabetic prevalence is high in countries in the Middle East and African region. The gradually growing obesity rate, combined with the genetic predisposition for Type-2 diabetes, acted as a prominent driver for the increase in the Type-2 diabetic population over the last 40 years. Currently, nearly 10% of the population is living with diabetes. Diabetic patients in the Middle East and African region mainly suffer from Type-2 diabetes, accounting for nearly 90% of the total diabetic population in 2021.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
